Realising the Commercial Potential of Implementing Pharmaceutical Co-Crystals into Your R&D Strategy
Pharmaceutical Co-Crystals are now being recognised as an attractive alternative route for solid state development. Through integration of a co-former partner into the crystal lattice, it is possible to manipulate the physico-chemical characteristics of the API thus enhancing properties such as solubility, dissolution rate, stability and bioavailability, which are integral to the effectiveness and success of future medicines. At present, achieving scale up of co-crystal production while maintaining the physico-chemical advantages which they afford is a major challenge in the pharmaceutical arena.
For that reason, Pharmaceutical Co-Crystals 2010 will explore the results and knowledge acquired over the years on perfecting the art of co-crystal formation and how best to apply it at both the laboratory and manufacturing scale, with the ultimate aim of realising the commercial potential of co-crystals in pharmaceutical drugs.
The Expert Speaker Panel includes:
Dr B N Roy, Head of Research & Development, Lupin Pharmaceuticals
Dr Peter Karpinski, Senior Principal Fellow, Novartis
Dr Simon Black, Principal Scientist, AstraZeneca
Associate Professor Nair Rodriguez-Hornedo, Department of Pharmaceutical Sciences, University of Michigan
Mr Bertrand Gellie, Director, The European Patent Office (EPO)
Dr Yaling Wang, Research Fellow, Merck
Dr Jeffrey Lindeman, J.A. Lindeman & Co. PLLC
Dr David Berry, Senior Scientist, Solid-State Development, AstraZeneca
Past Events
Pharmaceutical Co-Crystals 2010 - 27-28 Sep 2010, Movenpick Hotel Amsterdam City Centre, Netherlands (6701)
Pharmaceutical Co-Crystals 2026
Important
Please, check "Pharmaceutical Co-Crystals" official website for possible changes, before making any traveling arrangements
